Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

Two posters demonstrated that povorcitinib showed durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. This content was ...

Experts at the 2026 AAD Annual Meeting noted that, together, PCP support, community outreach, and teledermatology help reduce care gaps. This content was developed independently and is not endorsed by ...

Clinicians need to adjust their diagnostic lens and counseling strategies in patients with skin of color, explained Joseph Lam, MD. This content was developed independently and is not endorsed by the ...

Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis. This content was developed independently and is not endorsed by the American ...

Experts at the 2026 AAD Annual Meeting explained that teledermatology helps dermatologists manage their workload and expand patient access beyond traditional in-person care. Elizabeth Jones, MD, FAAD, ...

The study covers the period of 2015-2019 in Germany, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival ...

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous squamous cell carcinoma (CSCC) ...

The big question in administration of bispecific antibodies these days is how quickly they can move to the outpatient setting ...

Between 4.9 million and 10.1 million people enrolled in Medicaid expansion are projected to lose coverage in 2028 under the ...

The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent ...

This episode, titled ‘Navigating Benefit Design and Utilization Management in ATTR-CM,’ features the experts examining how ...